Upgrade to SI Premium - Free Trial

FDA Approves Bristol-Myers Squibb's (BMY) New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma

February 5, 2021 3:05 PM
(Updated - February 5, 2021 3:06 PM EST)Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot FDA News

Next Articles